AI4Eyes Medical Technologies has been operating with the patience of people who understand that credibility in medtech is earned, not announced. Built between Montreal and Vancouver, this AI-driven medical device company is focused on ocular diagnostics, a corner of healthcare where speed, accuracy, and consistency decide outcomes long before marketing ever gets a vote. Eyecare has lived with fragmented workflows, stacked devices, and slow feedback loops for years. AI4Eyes did not try to polish that system. They condensed it until it finally made sense.
In Q4 2025, AI4Eyes Medical Technologies secured $6.5M CAD through a disciplined internal financing round. $3.7M CAD came from existing shareholders, paired with $2.8M CAD in non-dilutive, government-backed funding. No debt. No valuation noise. Just capital aligned with execution. Part of that non-dilutive support runs through the Government of Canada and INOVAIT, where AI4Eyes was selected as 1 of only 17 Pilot Fund awardees nationwide. Selection at that level is not ceremonial. It is a signal that the work stands up under scrutiny.
The platform earns attention without asking for it. AI4Eyes consolidates 10 essential eye tests into a single 5-minute scan using patented high-resolution imaging and clinical-grade AI. Traditional workflows push past 30 minutes and still leave blind spots. More than 50% of patients walking into eye clinics have dry eye disease, yet only 8% are diagnosed under current systems. AI4Eyes drives diagnostic accuracy beyond 89%, integrates directly into existing clinic hardware, and keeps clinicians in full control of medical decisions. Less friction. Better data density. Fewer patients lost between appointments.
This capital is being deployed with precision. Regulatory pathways are accelerating across Canada and the US. Disease modules are expanding beyond dry eye into myopia and corneal conditions. The modular “Dr. App Store” software model allows clinics to pay per disease instead of absorbing bloated platforms. Partnerships with Starfish Medical, INOVAIT Canada, Integra Eyecare Network, and clinical advisors from UCLA Jules Stein Eye Institute and Harvard Eye Associates anchor the system in real-world medicine, not demo theater.
Leadership sets the rhythm. Dr. Tara Akhavan brings scale discipline and commercialization clarity as CEO. Dr. Henry Reis anchors clinical direction as Co-Founder and CMO, with deep roots in dry eye disease and eye care delivery. Daniel Hofmann guides strategy as Chairman, drawing on decades in ophthalmic pharma and medical devices. AI4Eyes is not chasing attention. It is building a diagnostic ecosystem that helps eye care finally see what has been hiding in plain sight.
